Serial PSMA PET Imaging in the Assessment of Treatment Response in Patients With Progressive Prostate Cancer
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.
• Patients with histologically confirmed prostate cancer, that is either: newly diagnosed OR progressive as defined by standard PCWG3 criteria. note that metastatic disease is defined by either bone scintigraphy or by CT or MRI, or a combination of these tests, but not exclusively by molecular imaging criteria.
• Patients with newly diagnosed localized or metastatic prostate cancer are eligible, provided standard imaging (either bone scintigraphy, CT or MRI) demonstrates evidence of radiographic disease
• Patient with progressive disease that is non-metastatic are eligible by biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart
• Patients with progressive disease that is metastatic are eligible either by biochemical progression or radiographic progression or both
• Patients are permitted to have had up to 2 months of prior hormonal therapy before entering this trial (and many therapeutic trials) and therefore, their progression criteria would apply to their pre-treatment imaging and PSA parameters
• Karnofsky performance status of >/= 50 (or ECOG/WHO equivalent)
• Male (or transgender female) > 18 years of age
• Patient must be able to understand and willing to sign a written informed consent document
• Patient is anticipating starting a therapeutic strategy following imaging